Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mediterranea Theranostic
Italy
- Ownership
- Private
- Development stage
- Other
01
Overview
Mediterranea Theranostic’s first anti-Trop-2 antibody-drug conjugate entered clinical trials in December 2023, in cancer patients at major cancer centers (Harvard’s Dana-Farber, MD Anderson), with clinical results for the LCB84 program expected in 2025. Preclinical validation showed strong anti-tumor efficacy, and a major license/partnership with LegoChem Biosciences accelerated development.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateMonoclonal antibody
- Industry
- Biotech
02
Partnerships
Oncoxx BiotechLegoChem BiosciencesJanssen (J&J)
Beyond the preview
Go deeper on Mediterranea Theranostic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mediterranea Theranostic.